UniQure has submitted its gene therapy for Huntington’s disease for regulatory review in the United Kingdom, marking the first such application for the company’s closely watched experimental treatment. The submission represents a critical step for the program as it faces an uncertain regulatory trajectory in the United States.
The therapy, which uses an adeno-associated virus (AAV) vector, aims to deliver a corrective gene to patients with Huntington's, a fatal inherited neurodegenerative disorder. The filing comes amid broader industry advances in AAV engineering and scalable manufacturing, which are improving the safety and accessibility of gene therapies, according to a recent report from Genetic Engineering News.
UniQure has not disclosed specific efficacy or safety data from the Huntington's program, and no timeline has been provided for a UK regulatory decision. The U.S. Food and Drug Administration had previously placed the therapy under clinical hold, raising questions about its domestic prospects.
Analysts describe the UK submission as largely symbolic given the small commercial opportunity in that market, but it may provide a regulatory pathway if the FDA remains skeptical. The company's stock could see volatility as investors weigh the fragmented global regulatory picture.
Patient advocacy groups have urged regulators to accelerate reviews of potential treatments for Huntington's, which currently has no disease-modifying therapies approved. However, experts caution that the durability and safety of gene therapies in the central nervous system remain unproven at scale.